Theravance Biopharma Inc. (TBPH)
NASDAQ: TBPH
· Real-Time Price · USD
14.53
-0.07 (-0.48%)
At close: Oct 01, 2025, 1:53 PM
-0.48% (1D)
| Bid | 14.51 |
| Market Cap | 731.75M |
| Revenue (ttm) | 77.2M |
| Net Income (ttm) | 13.03M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 58.12 |
| Forward PE | 48.1 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 14.53 |
| Volume | 143,710 |
| Avg. Volume (20D) | 365,911 |
| Open | 14.49 |
| Previous Close | 14.60 |
| Day's Range | 14.46 - 14.80 |
| 52-Week Range | 7.88 - 14.87 |
| Beta | 0.05 |
| Ex-Dividend Date | n/a |
About TBPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TBPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TBPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsTheravance Biopharma Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-9.29%
Theravance Biopharma shares are trading lower afte...
Unlock content with
Pro Subscription
10 months ago
+8.64%
Theravance Biopharma shares are trading higher after the company reported better-than-expected Q3 sales results.
1 month ago · seekingalpha.com
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call TranscriptTheravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - ...
